Sarcoma Study of MORAb-004 Utilization: Research and Clin... | NCT01574716

NCT01574716

ID	Type	Description	Link
2012-001399-12	EudraCT Number

Status Module

Sponsor/Collaborators Module

Oversight Module

No data available

No data is available for this block.

Description Module

Conditions Module

Design Module

Interventional Study Design

Biospecimen

No data available

No data is available for this block.

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
MORAb-004, gemcitabine, docetaxel	Experimental		Drug: MORAb-004 Drug: Gemcitabine Drug: Docetaxel
Placebo, gemcitabine, docetaxel	Active Comparator		Drug: Gemcitabine Drug: Docetaxel Drug: Placebo

Name	Type	Description	Arm Group Labels	Other Names
MORAb-004	Drug	IV, Days 1 and 8 of every cycle until disease progression	MORAb-004, gemcitabine, docetaxel

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Part 2: Radiologic Progression-free Survival (PFS)	PFS was defined as the time (in weeks) from the date of randomization to the date of first observation of disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or date of death, regardless of the cause.	From date of first dose until date of first observation of disease progression, or death due to any cause (up to approximately 3 years)

Secondary Outcomes

Measure	Description	Time Frame
Part 2: Symptomatic Progression-free Survival	PFS including symptomatic progression was defined as the time (in weeks) from the date of randomization to the date of the first observation of disease progression according to RECIST 1.1, symptomatic progression, or death due to any cause.	From date of first dose until date of first observation of disease progression, symptomatic progression, or death due to any cause (up to approximately 3 years)

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

Be at least 18 years of age
Be surgically sterile or consent to use a medically acceptable method of contraception throughout the study period
Have a histologically confirmed diagnosis of mSTS as defined by the 4 specified study subgrouped
Have been treated in the metastatic setting with 0 to 2 prior systemic regimens for mSTS (Systemic treatment regimens given in the neoadjuvant setting and maintenance therapies will not be considered as regimens in the metastatic setting for the purposes of this protocol. Prior anthracycline-based regimen is allowable but not required. Subjects with extra-skeletal small round blue cell sarcomas, including rhabdomyosarcomas, must have exhausted or be intolerant of standard first line anthracycline-based chemotherapy.)
Have measurable disease, as defined by RECIST v 1.1 assess within 2 weeks of study entry and have radiologically documented disease progression greater than or equal to a 10% increase in the sum of the longest diameters of target lesions present within 6 months prior to randomization
Have tumor tissue available for TEM-1 biomarker studies
Be willing and able to provide written informed consent

Exclusion Criteria:

Have received more than 2 prior systemic treatment regimens for mSTS
Have received either gemcitabine or docetaxel in any previous treatment for mSTS (regardless of the line of treatment)
Have a diagnosis of primary bone sarcoma of any histological type.
Have a history of clinically significant heart disease, or clinically significant arrhythmia on ECG within the past 6 months
Have a history of allergic reaction to prior monoclonal antibody or biologic agent
Have received previous treatment with MORAb-004 (anti-TEM-1)
Have a medical condition with a high risk of bleeding (e.g., a known bleeding disorder, a coagulopathy, or a tumor that involves the major vessels) or have a recent (within past 6 months) history of a significant bleeding event
Have undergone major surgical procedures or open biopsy, have significant traumatic injury within 30 days prior to the first date of study treatment, or have major surgical procedures anticipated during the study
Have a serious non-healing wound, an ulcer (including gastrointestinal), or a bone fracture

Contacts/Locations Module

Facility	Status	City	State	ZIP	Country	Contacts
Sarcoma Oncology Center		Santa Monica	California	90403	United States
UCLA

References Module

Citations

PubMed Identifier	Type	Citation	Retractions
31034598	Derived	Jones RL, Chawla SP, Attia S, Schoffski P, Gelderblom H, Chmielowski B, Le Cesne A, Van Tine BA, Trent JC, Patel S, Wagner AJ, Chugh R, Heyburn JW, Weil SC, Wang W, Viele K, Maki RG. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb-004) in metastatic soft-tissue sarcomas. Cancer. 2019 Jul 15;125(14):2445-2454. doi: 10.1002/cncr.32084. Epub 2019 Apr 29.

IPD Sharing Statement Module

No data available

No data is available for this block.

Results Section

Participant Flow Module

Arm/Group Information

ID	Title	Description
FG000	Part 1: MORAb-004 4.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 4 milligram per kilogram (mg/kg), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 milligram per square meter (mg/m^2), infusion, intravenously on Days 1 and 8 and docetaxel, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Baseline Characteristics Module

Outcome Measures Module

Adverse Events Module

More Info Module

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Submission Tracking

No data available

No data is available for this block.

Condition Browse Module

Intervention Browse Module

Masking Info

Part 1: The intent-to-treat (ITT)/Safety population (SP) included all treated participants and was analyzed by treatment dose level. Part 2: The ITT population consisted of all randomized participants and were analyzed according to the treatment assigned by the interactive randomization system (IxRS).

Arm/Group Information

ID	Title	Description
BG000	Part 1: MORAb-004 4.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 4 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
BG001	Part 1: MORAb-004 6.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 6 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
BG002	Part 1: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
BG003	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
BG004	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
BG005	Total	Total of all reporting groups

Baseline Measures

Title

Description

Population Description

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Denominator Units Selected

Denominators

Classes

Age, Categorical

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
<=18 years	BG0000 BG0010 BG0020 BG003

Sex: Female, Male

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Female	BG0002 BG0012 BG002

Ethnicity (NIH/OMB)

Count of Participants

Participants

Title

Denominators

Categories

Title	Measurements
Hispanic or Latino	BG0001 BG0010 BG002

Race/Ethnicity, Customized

Count of Participants

Participants

Title

Denominators

Categories

White

Title	Measurements
	BG0001 BG0013 BG002

Type

Title

Description

Population Description

Reporting Status

Anticipated Posting Date

Parameter Type

Dispersion Type

Unit of Measure

Calculate Percentage

Time Frame

Units Analyzed

Denominator Units Selected

Arm/Group Information

Denominators

Classes

Analyses

Primary

Part 2: Radiologic Progression-free Survival (PFS)

PFS was defined as the time (in weeks) from the date of randomization to the date of first observation of disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) or date of death, regardless of the cause.

The ITT population consisted of all randomized participants and were analyzed according to the treatment assigned by the IxRS.

Posted

Median

95% Confidence Interval

weeks

From date of first dose until date of first observation of disease progression, or death due to any cause (up to approximately 3 years)

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Units	Counts
Participants	OG000139 OG00170

Title

Denominators

Categories

Title	Measurements
	OG00018.7(11.6 to 27.4) OG00124.1(11.1 to 36.1)

Group IDs	Group Description	Statistical Method	Statistical Comment	P-Value	P-Value Comment	Parameter Type	Parameter Value	Dispersion Type	Dispersion Value	Confidence Interval Sides	Confidence Interval %	CI Lower Limit	CI Upper Limit	CI Lower Limit Comment	CI Upper Limit Comment	Estimate Comment	Tested Non-Inferiority	Non-Inferiority Type	Non-Inferiority Comment	Other Analysis Description
OG000 OG001		Log Rank	Two-sided log-rank test	= 0.6562		Hazard Ratio (HR)	1.08			2-Sided	95	0.77	1.50			Based on Cox PH model		Superiority

Secondary

Part 2: Symptomatic Progression-free Survival

PFS including symptomatic progression was defined as the time (in weeks) from the date of randomization to the date of the first observation of disease progression according to RECIST 1.1, symptomatic progression, or death due to any cause.

The ITT population consisted of all randomized participants and were analyzed according to treatment assigned by the IxRS.

Posted

Median

95% Confidence Interval

weeks

From date of first dose until date of first observation of disease progression, symptomatic progression, or death due to any cause (up to approximately 3 years)

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Secondary

Part 2: Overall Survival (OS)

OS was defined as the time (in months) from the date of randomization to the date of death, regardless of the cause.

The ITT Population consisted of all randomized participants and were analyzed according to treatment assigned by the IxRS.

Posted

Median

95% Confidence Interval

months

From date of first dose until date of death from any cause (up to approximately 3.5 years)

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Secondary

Part 2: Overall Response Rate (ORR)

ORR was defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) based on RECIST 1.1. CR was defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeter (mm). PR was defined as at least a 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum of diameters.

The ITT Population consisted of all randomized participants and were analyzed according to treatment assigned by the IxRS.

Posted

Number

percentage of participants

From date of first dose until disease progression (up to approximately 3.5 years)

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Secondary

Part 2: Radiologic Progression-free Survival Rate (PFR)

Radiologic progression-free survival rate was defined as the percentage of subjects achieving radiologic PFS at the pre-specified time points.

The ITT Population consisted of all randomized participants and were analyzed according to treatment assigned by the IxRS.

Posted

Number

percentage of participants

Weeks 12, 24, 48 and 52

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Secondary

Part 2: Number of Participants Who Had Relationship Between MORAb-004 Exposures and Biomarker Levels

The ITT Population consisted of all randomized participants and were analyzed according to treatment assigned by the IxRS.

Posted

Number

participants

Up to approximately 3 years

ID	Title	Description
OG000	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.
OG001	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.

Arm/Groups

ID	Title	Description	Deaths (Affected)	Deaths (At Risk)	Serious Events (Affected)	Serious Events (At Risk)	Other Events (Affected)	Other Events (At Risk)
EG000	Part 1: MORAb-004 4.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 4 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.	3	3	0	3	3	3
EG001	Part 1: MORAb-004 6.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 6 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.	1	4	1	4	4	4
EG002	Part 1: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle until disease progression (approximately 28 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.	8	9	6	9	9	9
EG003	Part 2: MORAb-004 8.0 mg/kg + Gemcitabine/Docetaxel	Participants received MORAb-004 8.0 mg/kg, infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). MORAb-004 was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.	76	140	106	140	140	140
EG004	Part 2: Placebo + Gemcitabine/Docetaxel	Participants received normal saline (0.9% sodium chloride), infusion, intravenously on Days 1 and 8 in combination with gemcitabine 900 mg/m^2, infusion, intravenously on Days 1 and 8 and docetaxel 75 mg/m^2, infusion, intravenously on Day 8 of each 21-day treatment cycle for until disease progression (approximately 31 cycles). Normal saline (0.9% sodium chloride) was administered after the administration of gemcitabine on Day 1 and after the administration of gemcitabine/docetaxel on Day 8 in each 21-day treatment cycle.	35	67	45	67	66	67

Serious Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG0035 affected140 at risk EG0044 affected67 at risk
Disseminated intravascular coagulation	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Febrile neutropenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Haemolytic uraemic syndrome	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Leukocytosis	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Leukopenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Neutropenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0023 affected9 at risk EG003
Atrial flutter	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Atrial thrombosis	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cardiac arrest	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cardiac failure	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Diastolic dysfunction	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pericardial effusion	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Sinus tachycardia	Cardiac disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Abdominal hernia	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Colitis	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Constipation	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Gastrointestinal pain	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Ileus	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Intussusception	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Oesophagitis	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pancreatic cyst	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Upper gastrointestinal haemorrhage	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Vomiting	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Chills	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Generalised oedema	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Infusion site extravasation	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Mucosal inflammation	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Non-cardiac chest pain	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Oedema peripheral	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pyrexia	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Systemic inflammatory response syndrome	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hepatic failure	Hepatobiliary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hepatotoxicity	Hepatobiliary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Portal vein thrombosis	Hepatobiliary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cytokine release syndrome	Immune system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypersensitivity	Immune system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Campylobacter gastroenteritis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cellulitis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Corona virus infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Enterocolitis infectious	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Escherichia sepsis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Influenza	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Liver abscess	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Lobar pneumonia	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Lung infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Neutropenic sepsis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumocystis jiroveci infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumocystis jiroveci pneumonia	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumonia	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Pneumonia primary atypical	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Respiratory tract infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Sepsis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Soft tissue infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Upper respiratory tract infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Urinary tract infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Wound infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Accidental overdose	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Clavicle fracture	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Femur fracture	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hip fracture	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Infusion related reaction	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Rib fracture	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Blood creatine phosphokinase increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Blood creatinine increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Neutrophil count decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Platelet count decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
White blood cell count decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Dehydration	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypoglycaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypophosphataemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypovolaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Groin pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Musculoskeletal chest pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Myositis	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Malignant pleural effusion	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Metastases to central nervous system	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Tumour pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Depressed level of consciousness	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Embolic stroke	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Encephalopathy	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Lethargy	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Memory impairment	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Peripheral motor neuropathy	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Presyncope	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Syncope	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Transient global amnesia	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Confusional state	Psychiatric disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Mental status changes	Psychiatric disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Haematuria	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hydronephrosis	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Renal failure	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Renal failure acute	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Haemothorax	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypoxia	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pleural effusion	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pleural haemorrhage	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumonitis	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumothorax	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pulmonary embolism	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pulmonary haemorrhage	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pulmonary oedema	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Respiratory failure	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Rash	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Capillary leak syndrome	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Deep vein thrombosis	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypertension	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypotension	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Vena cava thrombosis	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003

Other Adverse Events

Term	Organ System	Source Vocabulary	Assessment Type	Statistical Information
Anaemia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0011 affected4 at risk EG0028 affected9 at risk EG00385 affected140 at risk EG00437 affected67 at risk
Thrombocytopenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0003 affected3 at risk EG0010 affected4 at risk EG0028 affected9 at risk EG003
Neutropenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0024 affected9 at risk EG003
Leukopenia	Blood and lymphatic system disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Lacrimation Increased	Eye disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Nausea	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0011 affected4 at risk EG0025 affected9 at risk EG003
Constipation	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0011 affected4 at risk EG0022 affected9 at risk EG003
Abdominal pain	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0021 affected9 at risk EG003
Diarrhoea	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Vomiting	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0020 affected9 at risk EG003
Stomatitis	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Dyspepsia	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Abdominal Pain Upper	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Dry Mouth	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Gastrooesophageal Reflux Disease	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Fatigue	General disorders	MedDRA 14.1	Systematic Assessment	EG0003 affected3 at risk EG0013 affected4 at risk EG0026 affected9 at risk EG003
Oedema peripheral	General disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0022 affected9 at risk EG003
Pyrexia	General disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0011 affected4 at risk EG0024 affected9 at risk EG003
Chills	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Influenza Like Illness	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Mucosal Inflammation	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pain	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Asthenia	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Chest Pain	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Non-Cardiac Chest Pain	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Upper Respiratory Tract Infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Urinary Tract Infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Cellulitis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Nasopharyngitis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Pneumonia	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Sinusitis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Infusion Related Reaction	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Alanine Aminotransferase Increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0023 affected9 at risk EG003
Platelet Count Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Aspartate Aminotransferase Increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Blood Alkaline Phosphatase Increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Neutrophil Count Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
White Blood Cell Count Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Blood Creatinine Increased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Blood Albumin Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Lymphocyte Count Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Weight Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Blood Calcium Decreased	Investigations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Decreased appetite	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Hypokalaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0023 affected9 at risk EG003
Hyperglycaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Dehydration	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Hypoalbuminaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Hypomagnesaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hyponatraemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypocalcaemia	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Back pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0013 affected4 at risk EG0021 affected9 at risk EG003
Pain in extremity	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0021 affected9 at risk EG003
Arthralgia	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0013 affected4 at risk EG0020 affected9 at risk EG003
Myalgia	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Bone Pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Musculoskeletal Pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Musculoskeletal Chest Pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Headache	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0012 affected4 at risk EG0023 affected9 at risk EG003
Dysgeusia	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Dizziness	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Neuropathy Peripheral	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Paraesthesia	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Peripheral Sensory Neuropathy	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Insomnia	Psychiatric disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Anxiety	Psychiatric disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Depression	Psychiatric disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Cough	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Dyspnoea	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Epistaxis	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0022 affected9 at risk EG003
Dyspnoea Exertional	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Pleural Effusion	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Alopecia	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0002 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Rash	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Pruritus	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Rash Maculo-Papular	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Dry Skin	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Erythema	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hypertension	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Hot Flush	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Flushing	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Hypotension	Vascular disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Deafness Unilateral	Ear and labyrinth disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Ear Pain	Ear and labyrinth disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Tinnitus	Ear and labyrinth disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Conjunctivitis	Eye disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Dry Eye	Eye disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Vision Blurred	Eye disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Dental Caries	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Flatulence	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Frequent Bowel Movements	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Peptic Ulcer	Gastrointestinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Catheter Site Rash	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Early Satiety	General disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Hyperbilirubinaemia	Hepatobiliary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Diverticulitis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Gastrointestinal Viral Infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Lower Respiratory Tract Infection Viral	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Oral Candidiasis	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Staphylococcal Skin Infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Viral Upper Respiratory Tract Infection	Infections and infestations	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Contusion	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0012 affected4 at risk EG0020 affected9 at risk EG003
Tooth Fracture	Injury, poisoning and procedural complications	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Increased Appetite	Metabolism and nutrition disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Groin Pain	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Metatarsalgia	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Muscle Twitching	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Musculoskeletal Stiffness	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Pain In Jaw	Musculoskeletal and connective tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Tumour Pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Hyperaesthesia	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Loss Of Consciousness	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Neuralgia	Nervous system disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Dysuria	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Urinary Tract Obstruction	Renal and urinary disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0020 affected9 at risk EG003
Haemoptysis	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0022 affected9 at risk EG003
Hiccups	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003
Hypoxia	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Nasal Congestion	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Oropharyngeal Discomfort	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Rhinitis Allergic	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Wheezing	Respiratory, thoracic and mediastinal disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Hyperhidrosis	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0001 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Nail Disorder	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Night Sweats	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0021 affected9 at risk EG003
Rash Pruritic	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0010 affected4 at risk EG0021 affected9 at risk EG003
Skin Exfoliation	Skin and subcutaneous tissue disorders	MedDRA 14.1	Systematic Assessment	EG0000 affected3 at risk EG0011 affected4 at risk EG0020 affected9 at risk EG003

ID	Term
D012509	Sarcoma

ID	Term
C000604563	ontuxizumab
D000093542	Gemcitabine
D000077143	Docetaxel

Ancestor Terms

ID	Term
D006571	Heterocyclic Compounds
D003841	Deoxycytidine
D003562	Cytidine
D011741	Pyrimidine Nucleosides
D011743	Pyrimidines
D006573	Heterocyclic Compounds, 1-Ring
D043823	Taxoids
D043822	Cyclodecanes
D003516	Cycloparaffins
D006840	Hydrocarbons, Alicyclic
D006844	Hydrocarbons, Cyclic
D006838	Hydrocarbons
D009930	Organic Chemicals
D004224	Diterpenes
D013729	Terpenes

Units	Counts
Participants	OG000139 OG00170

EG0041 affected67 at risk

EG0042 affected67 at risk

EG0040 affected67 at risk

EG0042 affected67 at risk

EG0043 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0042 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0042 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0043 affected67 at risk

EG0040 affected67 at risk

EG0042 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0046 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0043 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0043 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0043 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0042 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG0041 affected67 at risk

EG0040 affected67 at risk

EG00428 affected67 at risk

EG00415 affected67 at risk

EG00411 affected67 at risk

EG0046 affected67 at risk

EG00434 affected67 at risk

EG00425 affected67 at risk

EG00415 affected67 at risk

EG00424 affected67 at risk

EG00411 affected67 at risk

EG0045 affected67 at risk

EG0042 affected67 at risk

EG0046 affected67 at risk

EG0045 affected67 at risk

EG0044 affected67 at risk

EG00444 affected67 at risk

EG00429 affected67 at risk

EG00417 affected67 at risk

EG0043 affected67 at risk

EG0042 affected67 at risk

EG0046 affected67 at risk

EG0044 affected67 at risk

EG0042 affected67 at risk

EG0041 affected67 at risk

EG0043 affected67 at risk

EG0044 affected67 at risk

EG0043 affected67 at risk

EG0042 affected67 at risk

EG0041 affected67 at risk

ID	Term
D018204	Neoplasms, Connective and Soft Tissue
D009370	Neoplasms by Histologic Type
D009369	Neoplasms